First Catheter-Delivered iPS Cardiomyocyte Spheroid Case Completed: How Heartseed’s HS-005 Advances Minimally Invasive Regenerative Care for Heart Failure
Japan has completed the first catheter-delivered administration of iPS-derived cardiomyocyte spheroids. A look at the EMERALD trial, the difference between HS-001 and HS-005, and the wider cardiac regenerative-medicine landscape after ReHeart’s approval.